Skip to main content
  • ASM Journals
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Latest Articles
    • Special Issues
    • COVID-19 Special Collection
    • Special Series: Sponsored Minireviews and Video Abstracts
    • Archive
  • Topics
    • Applied and Environmental Science
    • Ecological and Evolutionary Science
    • Host-Microbe Biology
    • Molecular Biology and Physiology
    • Novel Systems Biology Techniques
    • Early-Career Systems Microbiology Perspectives
  • For Authors
    • Getting Started
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics
  • About the Journal
    • About mSystems
    • Editor in Chief
    • Board of Editors
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • ASM Journals
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
mSystems
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Latest Articles
    • Special Issues
    • COVID-19 Special Collection
    • Special Series: Sponsored Minireviews and Video Abstracts
    • Archive
  • Topics
    • Applied and Environmental Science
    • Ecological and Evolutionary Science
    • Host-Microbe Biology
    • Molecular Biology and Physiology
    • Novel Systems Biology Techniques
    • Early-Career Systems Microbiology Perspectives
  • For Authors
    • Getting Started
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics
  • About the Journal
    • About mSystems
    • Editor in Chief
    • Board of Editors
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
Research Article | Host-Microbe Biology

Alterations in the Gut Microbiome in the Progression of Cirrhosis to Hepatocellular Carcinoma

Yelena Lapidot, Amnon Amir, Rita Nosenko, Atara Uzan-Yulzari, Ella Veitsman, Oranit Cohen-Ezra, Yana Davidov, Peretz Weiss, Tanya Bradichevski, Shlomo Segev, Omry Koren, Michal Safran, Ziv Ben-Ari
Chaysavanh Manichanh, Editor
Yelena Lapidot
aLiver Research Laboratory, Sheba Medical Center, Tel Hashomer, Israel
bLiver Diseases Center, Sheba Medical Center, Tel Hashomer, Israel
cThe Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Yelena Lapidot
Amnon Amir
dCancer Research Center, Sheba Medical Center, Tel Hashomer, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rita Nosenko
eFaculty of Medicine, Bar-Ilan University, Safed, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Atara Uzan-Yulzari
eFaculty of Medicine, Bar-Ilan University, Safed, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ella Veitsman
bLiver Diseases Center, Sheba Medical Center, Tel Hashomer, Israel
fLiver Diseases Center, Rambam Health Care Campus, Haifa, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Oranit Cohen-Ezra
bLiver Diseases Center, Sheba Medical Center, Tel Hashomer, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yana Davidov
bLiver Diseases Center, Sheba Medical Center, Tel Hashomer, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peretz Weiss
bLiver Diseases Center, Sheba Medical Center, Tel Hashomer, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tanya Bradichevski
bLiver Diseases Center, Sheba Medical Center, Tel Hashomer, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shlomo Segev
gMedical Screening Unit, Sheba Medical Center, Tel Hashomer, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Omry Koren
eFaculty of Medicine, Bar-Ilan University, Safed, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michal Safran
aLiver Research Laboratory, Sheba Medical Center, Tel Hashomer, Israel
bLiver Diseases Center, Sheba Medical Center, Tel Hashomer, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ziv Ben-Ari
aLiver Research Laboratory, Sheba Medical Center, Tel Hashomer, Israel
bLiver Diseases Center, Sheba Medical Center, Tel Hashomer, Israel
cThe Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chaysavanh Manichanh
Vall d'Hebron Research Institute (Ed. Mediterranea)
Roles: Editor
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jiajia Ni
Zhujiang Hospital of Southern Medical University
Roles: ad hoc peer reviewer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jiajia Ni
DOI: 10.1128/mSystems.00153-20
  • Article
  • Figures & Data
  • Info & Metrics
  • Review History
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Supplemental Material
  • FIG 1
    • Open in new tab
    • Download powerpoint
    FIG 1

    Gut microbiome alterations in patients with cirrhosis or HCC-cirrhosis and in controls and cirrhosis etiology distribution in study groups. (A) Box plot of α-diversity (observed features) displaying a significant decrease in bacterial richness in cirrhotic patients and patients with HCC-cirrhosis compared to healthy controls (P values = 0.014 and 0.028, correspondingly). (B) Box plot of β-diversity (unweighted UniFrac distance) displaying a significant difference in bacterial composition in cirrhotic patients and patients with HCC-cirrhosis compared to healthy controls (P values = 0.004 and 0.016, correspondingly). (C and D) Box plot of α-diversity (observed OTU indices) (C) and β-diversity (unweighted UniFrac distance matrix) (D) of cirrhosis etiologies (in cirrhosis without HCC), displaying a significant decrease in bacterial richness (P value = 0.04) and altered bacterial composition (P value = 0.03) in cirrhotic patients with NAFLD compared to HCV-cirrhosis patients. (E and F) Box plot of α-diversity (observed OTU indices) (E) and β-diversity (unweighted UniFrac distance matrix) (F) of HCC-cirrhosis etiologies (in the HCC-cirrhosis group), showing that there were no significant differences in bacterial richness (P value = 0.11) or composition (P value = 0.07) in HCC patients with NAFLD-cirrhosis compared to HCV-cirrhosis.

  • FIG 2
    • Open in new tab
    • Download powerpoint
    FIG 2

    Differentially abundant taxa in patients with HCC-cirrhosis compared to the controls. (A) LDA scores computed for differentially abundant taxa in the fecal microbiomes of patients with HCC-cirrhosis (green) and healthy controls (red). Length indicates effect size associated with a taxon. P = 0.05 for the Kruskal-Wallis test; LDA score > 2. (B) A graphical representation of the classification accuracy of a machine-learning random forest model in receiver operating characteristic (ROC) curves, displayed here as ROC curves for each class (AUC of 0.9) and average ROCs and AUCs, including “microaveraging” of 0.87 (to calculate metrics globally by averaging across each sample) and “macroaveraging” of 0.94 (to give equal weight to the classification of each sample). (C) Confusion matrix displaying the classification results, with overall accuracy of 82%, baseline accuracy of 0.545, and an accuracy ratio of 1.5. (D) Important features are represented in an abundance heat map, consisting of log10 frequencies of the most important taxa in each sample and group (HCC-cirrhosis and healthy controls). These are the features that maximize model accuracy, as determined using recursive feature elimination.

  • FIG 3
    • Open in new tab
    • Download powerpoint
    FIG 3

    Differentially abundant taxa in patients with HCC-cirrhosis compared to cirrhotic patients without HCC. (A) LDA scores computed for differentially abundant taxa in the fecal microbiomes of patients with liver cirrhosis (red) and patients with HCC-cirrhosis (green). Length indicates effect size associated with a taxon. P = 0.05 for the Kruskal-Wallis test; LDA score > 2. (B) Taxonomic cladogram from LEfSe showing differences in fecal taxa of cirrhosis patients compared to HCC-cirrhosis patients. There were differences in the relative abundances of Alphaproteobacteria (P value = 0.039), Clostridium (P value = 0.024), CF231 (P value = 0.010), Verrucomicrobia (P value = 0.036), and Akkermansia muciniphila (P value = 0.039).

  • FIG 4
    • Open in new tab
    • Download powerpoint
    FIG 4

    Gut microbiome alterations in overweight HCC-cirrhosis patients. (A) Box plot of α-diversity (Shannon’s index) displaying a significant decrease in diversity in patients with HCC-cirrhosis that were overweight (BMI > 25) compared to counterparts that were not overweight (P value = 0.024). (B) Box plot of β-diversity displaying a significant difference in bacterial composition in overweight patients with HCC-cirrhosis compared to counterparts that were not overweight (P value = 0.033). (C) LDA scores computed for differentially abundant taxa in the fecal microbiomes of overweight patients with HCC-cirrhosis. Length indicates effect size associated with a taxon. P = 0.05 for the Kruskal-Wallis test; LDA score > 2.

  • FIG 5
    • Open in new tab
    • Download powerpoint
    FIG 5

    Fatty liver in HCC-cirrhosis and significant association with the relative abundance of Akkermansia. (A) Box plot of α-diversity (Faith’s phylogenetic diversity [PD]) displaying a significant decrease in diversity in patients with HCC-cirrhosis that had a fatty liver compared to counterparts without a fatty liver (P value = 0.025). (B) Box plot of β-diversity (unweighted UniFrac distance matrix) displaying a significant difference in bacterial composition in patients with HCC-cirrhosis that had a fatty liver compared to counterparts without a fatty liver (P value = 0.008). (C) LDA scores computed for differentially abundant taxa in the fecal microbiomes of patients with HCC-cirrhosis that had a fatty liver. Length indicates effect size associated with a taxon. P = 0.05 for the Kruskal-Wallis test; LDA score > 2.

Tables

  • Figures
  • Supplemental Material
  • TABLE 1

    Demographic and clinical characterization of study groupsa

    TABLE 1
    • ↵a One-way analysis of variance was used to evaluate the difference among the three groups. Continuous variables were compared using the Wilcoxon-Mann-Whitney rank sum test for comparisons between patient groups. Fisher’s exact test was used to compare categorical variables. NA, not applicable.

Supplemental Material

  • Figures
  • Tables
  • FIG S1

    Weighted phylogenetic β-diversity analysis. Box plots of phylogenetic β-diversity measured by weighted UniFrac distance matrix, displaying no significant differences between study groups (cirrhosis compared to controls P value = 0.243, HCC-cirrhosis compared to controls P value = 0.263, cirrhosis compared to HCC-cirrhosis P value = 0.117). Download FIG S1, TIF file, 1.1 MB.

    Copyright © 2020 Lapidot et al.

    This content is distributed under the terms of the Creative Commons Attribution 4.0 International license.

  • FIG S2

    Gut microbial composition in association with cirrhosis severity. (A) Box plot of β-diversity (unweighted UniFrac distance matrix) displaying a significant difference in bacterial composition according to cirrhosis severity in compensated cirrhosis and decompensated cirrhosis (P value = 0.024). (B) LDA scores computed for differentially abundant taxa in the fecal microbiomes of patients with compensated cirrhosis (red) and decompensated cirrhosis (green). Length indicates effect size associated with a taxon (P = 0.05 for the Kruskal-Wallis test; LDA score > 2). (C) Taxonomic cladogram from LEfSe showing differences in fecal taxa of cirrhotic patients according to disease severity. Dot size is proportional to the abundance of the taxon. Download FIG S2, TIF file, 2.0 MB.

    Copyright © 2020 Lapidot et al.

    This content is distributed under the terms of the Creative Commons Attribution 4.0 International license.

  • FIG S3

    Gut microbial composition in association with diuretics in cirrhosis. (A) Box plot of α-diversity (observed features) displaying a significant decrease in diversity in cirrhotic patients that received diuretics compared to counterparts that did not receive diuretics (P value = 0.003). (B) Box plot of β-diversity (unweighted UniFrac distance matrix) displaying a significant difference in bacterial composition in cirrhotic patients that received diuretics compared to counterparts that did not receive diuretics (P value = 0.006). (C) Taxonomic cladogram from LEfSe showing differences in fecal taxa of cirrhotic patients (compensated and decompensated cirrhosis). Patients with cirrhosis receiving diuretics exhibited marked alterations in the abundances of various bacteria, including an increased relative abundance of Bacilli (P value = 0.031). Dot size is proportional to the abundance of the taxon. (D) Taxonomic cladogram showing alterations in fecal microbiome of patients with decompensated cirrhosis receiving diuretics. Download FIG S3, TIF file, 2.0 MB.

    Copyright © 2020 Lapidot et al.

    This content is distributed under the terms of the Creative Commons Attribution 4.0 International license.

  • FIG S4

    High-protein-diet consumption in patients with cirrhosis is associated with microbial alterations. (A) Box plot of α-diversity (observed features) displaying a significant decrease in diversity in cirrhotic patients that consumed a high-protein diet compared to counterparts that did not consume a high-protein diet (P value = 0.003). (B) Box plot of β-diversity (unweighted UniFrac distance matrix) displaying a significant difference in bacterial composition in cirrhotic patients who reported consumption of a high-protein diet compared to counterparts who did not report consumption of a high-protein diet (P value = 0.009). (C) Taxonomic cladogram from LEfSe showing differences in fecal taxa of cirrhotic patients according to disease severity. Dot size is proportional to the abundance of the taxon. (D) LDA scores computed for differentially abundant taxa in the fecal microbiomes of patients with compensated cirrhosis (red) and decompensated cirrhosis (green). Length indicates effect size associated with a taxon (P = 0.05 for the Kruskal-Wallis test; LDA score > 2). Download FIG S4, TIF file, 2.0 MB.

    Copyright © 2020 Lapidot et al.

    This content is distributed under the terms of the Creative Commons Attribution 4.0 International license.

  • TABLE S1

    Study questionnaire. Download Table S1, DOCX file, 2.0 MB.

    Copyright © 2020 Lapidot et al.

    This content is distributed under the terms of the Creative Commons Attribution 4.0 International license.

  • TABLE S2

    Significantly altered bacteria in patients with cirrhosis compared to healthy controls. Download Table S2, DOCX file, 0.01 MB.

    Copyright © 2020 Lapidot et al.

    This content is distributed under the terms of the Creative Commons Attribution 4.0 International license.

  • TABLE S3

    Correlation analysis of food frequency questionnaires and gut bacteria in cirrhosis group. Spearman correlation analysis was performed for comparisons between parameters of food frequency questionnaires and fecal bacteria at the genus level in the HCC-cirrhosis group. In this table, the strongest correlations that corresponded to a P value of >0.05 are presented. These correlations did not pass the multiple-comparison correction test (false-discovery-rate [q] value < 0.05). Download Table S3, DOCX file, 0.01 MB.

    Copyright © 2020 Lapidot et al.

    This content is distributed under the terms of the Creative Commons Attribution 4.0 International license.

  • TABLE S4

    Significantly altered bacterial composition in patients with HCC-cirrhosis compared to healthy volunteers. Download Table S4, DOCX file, 0.01 MB.

    Copyright © 2020 Lapidot et al.

    This content is distributed under the terms of the Creative Commons Attribution 4.0 International license.

  • TABLE S5

    Feature importance analysis for random forest classifier in comparisons between HCC and healthy controls. Download Table S5, DOCX file, 0.01 MB.

    Copyright © 2020 Lapidot et al.

    This content is distributed under the terms of the Creative Commons Attribution 4.0 International license.

  • TABLE S6

    Correlation analysis of food frequency questionnaires and gut bacteria in the HCC-cirrhosis group: Spearman correlation analysis between parameters of food frequency questionnaires and fecal bacteria at the genus level in the HCC-cirrhosis group. In this table, the strongest correlations that received a P value of >0.05 are presented. Two of these correlations passed the multiple-comparison correction test (q value < 0.05): consumption of artificial sweeteners was significantly correlated with Verrucomicrobia genus Akkermansia muciniphila and consumption of products containing large amounts of sugar with Synergistetes genus Cloacibacillus. Download Table S6, DOCX file, 0.01 MB.

    Copyright © 2020 Lapidot et al.

    This content is distributed under the terms of the Creative Commons Attribution 4.0 International license.

PreviousNext
Back to top
Download PDF
Citation Tools
Alterations in the Gut Microbiome in the Progression of Cirrhosis to Hepatocellular Carcinoma
Yelena Lapidot, Amnon Amir, Rita Nosenko, Atara Uzan-Yulzari, Ella Veitsman, Oranit Cohen-Ezra, Yana Davidov, Peretz Weiss, Tanya Bradichevski, Shlomo Segev, Omry Koren, Michal Safran, Ziv Ben-Ari
mSystems Jun 2020, 5 (3) e00153-20; DOI: 10.1128/mSystems.00153-20

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print
Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this mSystems article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Alterations in the Gut Microbiome in the Progression of Cirrhosis to Hepatocellular Carcinoma
(Your Name) has forwarded a page to you from mSystems
(Your Name) thought you would be interested in this article in mSystems.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Alterations in the Gut Microbiome in the Progression of Cirrhosis to Hepatocellular Carcinoma
Yelena Lapidot, Amnon Amir, Rita Nosenko, Atara Uzan-Yulzari, Ella Veitsman, Oranit Cohen-Ezra, Yana Davidov, Peretz Weiss, Tanya Bradichevski, Shlomo Segev, Omry Koren, Michal Safran, Ziv Ben-Ari
mSystems Jun 2020, 5 (3) e00153-20; DOI: 10.1128/mSystems.00153-20
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • INTRODUCTION
    • RESULTS
    • DISCUSSION
    • MATERIALS AND METHODS
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • Review History
  • PDF

KEYWORDS

diet
A. muciniphila
cirrhosis
hepatocellular carcinoma
microbiome
gut microbiome

Related Articles

Cited By...

About

  • About mSystems
  • Author Videos
  • Board of Editors
  • Policies
  • Overleaf Pilot
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Author Warranty
  • Types of Articles
  • Getting Started
  • Ethics
  • Contact Us

Follow #mSystemsJ

@ASMicrobiology

       

 

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Online ISSN: 2379-5077